Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies
Abstract Pemigatinib is a potent inhibitor of the fibroblast growth factor receptor (FGFR) family of receptors that is approved for the treatment of cholangiocarcinoma with FGFR2 fusion or other rearrangements. Data from a first‐in‐human clinical study were used to assess the potential for pemigatin...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Llibre |
| Publicat: |
Wiley,
2022-02-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |